Clinical Trial Search

Primary: Improvement in Investigator Assessment of Overall Global Aesthetic Improvement Scale (GAI) — 61; 68 percentage of participants

Primary: Event-free Survival Rate — 90.4; 83.9 Percentage of participants — p=<0.01

Primary: Weekly Percentage of Heavy Drinking Days — 37.9; 48.4 percentage of heavy drinking days

Primary: Mean Ocular Itching at Onset of Action — 0.38; 0.47; 0.59; 1.91 units on a scale

Primary: Mean in the Prefrontal Executive Function Z-score (PEF6_6) — 0.121; 0.213; 0.270 Z-score — p=0.06

Primary: Objective Response Rate (PR + CR) Using RECIST/WHO Response Criteria — 0; 0; 0; 0 percentage of participants

Primary: Cmax — 51.04; 61.41 ng/ml

Primary: Percentage of Responders After 5 Months After the Procedure — 37; 34 percentage of participants

Primary: Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells During the First 12 Weeks of Study — 0.03; -0.01 Log10(percentage of T cells) — p=0.63

Primary: The Primary Objective of This Trial is to Compare the Impact of Disinfecting the Skin With Chloraprep vs. Betadine on the Rates of Infection of Clean-contaminated…

Primary: Time (Hours) to First Use of Rescue Medication — NA; NA; NA hours — p=0.6407

Primary: Population Estimates for Daunorubicin Hydrochloride Clearance — 116 L/m2/hr

Primary: Degree of Leakage — 5.0; 5.6 units on a scale

Primary: Mean Change in Fluorescein Staining Score From Baseline — -2.12; -2.08 points

Primary: Percentage of Patients With Chemotherapy-induced Sensory Peripheral Neuropathy ≥ Grade 2 — 34; 29 percentage of participants — p=0.43